Hepatocellular Carcinoma Supplied by the Inferior Phrenic Artery or Cystic Artery: Anatomic and Technical Considerations

医学 肋间动脉 囊性动脉 肝细胞癌 放射科 栓塞 动脉 支气管动脉 经导管动脉化疗栓塞 分流(医疗) 胆囊 外科 胆囊管 内科学
作者
Hyo‐Cheol Kim,Shiro Miyayama,Jin Woo Choi,Gyoung Min Kim,Jin Wook Chung
出处
期刊:Radiographics [Radiological Society of North America]
卷期号:43 (1) 被引量:11
标识
DOI:10.1148/rg.220076
摘要

Intra-arterial treatment has been identified as one of the mainstays in the management of unresectable hepatocellular carcinoma. A thorough knowledge of tumor arterial supply enables selective therapy, which improves both safety and efficacy. The inferior phrenic artery (IPA) is the most common extrahepatic collateral artery that feeds hepatocellular carcinoma. The bilateral IPAs are known to have a specific vascular anatomy. A systemic-to-pulmonary shunt and a gastric branch from the IPAs may be present and should not be confused with tumor blush. The supraceliac aorta and celiac trunk are the common origin sites of the IPAs, and their orifice may be compressed by the diaphragm. Various techniques and catheters are used for catheterization of the IPAs, depending on their origin sites. Because the IPA is normally connected with the intercostal, internal mammary, retroperitoneal, and hepatic arteries, its hemodynamics may be altered when its orifice is occluded. In general, superselective chemoembolization via the target branch of the IPA is safe and effective. When a systemic-to-pulmonary shunt from the IPA is adequately embolized with coils or particles, radioembolization through the IPA can be performed safely in most cases. The cystic artery branches into deep and superficial cystic arteries; deep cystic arteries often supply tumors near the gallbladder. Chemoembolization through the cystic artery is relatively safe, with transient embolic materials. Radioembolization through the cystic artery has been recently tried, with acceptable efficacy and toxicity results, but it requires further investigation. ©RSNA, 2022.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
5秒前
BCKT完成签到,获得积分10
5秒前
5秒前
6秒前
斯文败类应助半夏采纳,获得10
7秒前
星辰大海应助清秀曼彤采纳,获得10
8秒前
Orange应助冷静的小虾米采纳,获得10
9秒前
好好科研~完成签到 ,获得积分10
9秒前
研友_VZG7GZ应助别凡采纳,获得10
10秒前
虾米发布了新的文献求助10
11秒前
碎尘发布了新的文献求助10
11秒前
11秒前
Ava应助雪菜采纳,获得10
13秒前
廉凌波发布了新的文献求助10
13秒前
忧伤的真菌完成签到 ,获得积分10
13秒前
小二郎应助科研通管家采纳,获得10
14秒前
良辰应助科研通管家采纳,获得10
14秒前
Akim应助科研通管家采纳,获得10
14秒前
良辰应助科研通管家采纳,获得10
14秒前
充电宝应助科研通管家采纳,获得10
14秒前
深情安青应助科研通管家采纳,获得10
14秒前
Orange应助科研通管家采纳,获得10
15秒前
NexusExplorer应助科研通管家采纳,获得10
15秒前
良辰应助科研通管家采纳,获得10
15秒前
852应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
miles发布了新的文献求助10
15秒前
Melody完成签到,获得积分10
16秒前
糊涂涂完成签到,获得积分10
17秒前
cocolu应助廉凌波采纳,获得10
17秒前
18秒前
19秒前
19秒前
斯文败类应助Tracy采纳,获得10
20秒前
幽默的月光完成签到,获得积分10
21秒前
szz完成签到,获得积分10
21秒前
可靠的碧凡完成签到 ,获得积分10
22秒前
思源应助000采纳,获得10
23秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger Heßler, Claudia, Rud 1000
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 1000
Natural History of Mantodea 螳螂的自然史 1000
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
How Maoism Was Made: Reconstructing China, 1949-1965 800
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 量子力学 冶金 电极
热门帖子
关注 科研通微信公众号,转发送积分 3316498
求助须知:如何正确求助?哪些是违规求助? 2948223
关于积分的说明 8539677
捐赠科研通 2624118
什么是DOI,文献DOI怎么找? 1435867
科研通“疑难数据库(出版商)”最低求助积分说明 665703
邀请新用户注册赠送积分活动 651634